Literature DB >> 31445220

Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers.

Yue Zhao1, Jiahui Li2, Dai Li3, Zhefang Wang2, Jiangang Zhao4, Xiaolin Wu2, Qiye Sun2, Peter Ping Lin5, Patrick Plum6, Alexander Damanakis2, Florian Gebauer2, Menglong Zhou7, Zhen Zhang7, Hans Schlösser8, Karl-Walter Jauch9, Peter J Nelson10, Christiane J Bruns11.   

Abstract

More than 70% of gastrointestinal (GI) cancers are diagnosed with metastases, leading to poor prognosis. For some cancer patients with limited sites of metastatic tumors, the term oligometastatic disease (OMD) has been coined as opposed to systemic polymetastasis (PMD) disease. Stephan Paget first described an organ-specific pattern of metastasis in 1889, now known as the "seed and soil" theory where distinct cancer types are found to metastasize to different tumor-specific sites. Our understanding of the biology of tumor metastasis and specifically the molecular mechanisms driving their formation are still limited, in particular, as it relates to the genesis of oligometastasis. In the following review, we discuss recent advances in general understanding of this metastatic behavior including the role of specific signaling pathways, various molecular features and biomarkers, as well as the interaction of carcinoma cells with their tissue microenvironments (both primary and metastatic niches). The unique features that underlie OMD provide potential targets for localized therapy. As it relates to clinical practice, OMD is emerging as treatable with surgical resection and/or other local therapy options. Strategies currently being applied in the clinical management of OMD will be discussed including surgical, radiation-based therapy, ablation procedures, and the results of emerging clinical trials involving immunotherapy.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Biomarkers; Molecular biology; Oligometastasis; Radiation therapy; Surgery

Year:  2019        PMID: 31445220     DOI: 10.1016/j.semcancer.2019.08.026

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  15 in total

1.  LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway.

Authors:  Yuen Tan; Qingchuan Chen; Siwei Pan; Wen An; Huimian Xu; Yao Xing; Jianjun Zhang
Journal:  BMC Cancer       Date:  2022-04-30       Impact factor: 4.638

2.  CD44+ Circulating Tumor Endothelial Cells Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After Radical Surgery: A Pilot Study.

Authors:  Cheng Xing; Yatong Li; Cheng Ding; Shunda Wang; Hanyu Zhang; Lixin Chen; Pengyu Li; Menghua Dai
Journal:  Cancer Manag Res       Date:  2021-06-01       Impact factor: 3.989

Review 3.  Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis.

Authors:  Peter Ping Lin
Journal:  Cells       Date:  2020-06-24       Impact factor: 6.600

4.  ELAVL1 is transcriptionally activated by FOXC1 and promotes ferroptosis in myocardial ischemia/reperfusion injury by regulating autophagy.

Authors:  Hui-Yong Chen; Ze-Zhou Xiao; Xiao Ling; Rong-Ning Xu; Peng Zhu; Shao-Yi Zheng
Journal:  Mol Med       Date:  2021-02-10       Impact factor: 6.376

Review 5.  Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development.

Authors:  William H Gmeiner
Journal:  Onco Targets Ther       Date:  2021-03-25       Impact factor: 4.147

Review 6.  Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities.

Authors:  Mahshad Sarvizadeh; Omid Hasanpour; Zari Naderi Ghale-Noie; Samaneh Mollazadeh; Mohammad Rezaei; Hossein Pourghadamyari; Mohammadjaber Masoud Khooy; Michael Aschner; Haroon Khan; Nima Rezaei; Layla Shojaie; Hamed Mirzaei
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

7.  Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

Authors:  Florian Gebauer; Alexander Ioannis Damanakis; Dirk Waldschmidt; Christiane Bruns; Felix Popp; Alexander Quaas; Fabian Kütting; Katrin Lutz; Swantje Held; Burkhard Deuß; Tobias Göser
Journal:  BMC Cancer       Date:  2021-11-18       Impact factor: 4.430

Review 8.  Prognostic and Predictive Biomarkers in Oligometastatic Disease.

Authors:  Kevin J Barnum; Sarah A Weiss
Journal:  Cancer J       Date:  2020 Mar/Apr       Impact factor: 2.074

9.  Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer.

Authors:  Yuanyuan Lei; Nan Sun; Guochao Zhang; Chengming Liu; Zhiliang Lu; Jianbing Huang; Chaoqi Zhang; Ruochuan Zang; Yun Che; Shuangshuang Mao; Lingling Fang; Xinfeng Wang; Sufei Zheng; Jie He
Journal:  Clin Transl Med       Date:  2020-07-13

Review 10.  Role of reactive oxygen species in tumors based on the 'seed and soil' theory: A complex interaction (Review).

Authors:  Wei Liang; Xinying He; Jianqiang Bi; Tingting Hu; Yunchuan Sun
Journal:  Oncol Rep       Date:  2021-07-30       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.